EMPA-KIDNEY

EMPA-KIDNEY is a clinical trial initiated by scientists based at the Medical Research Council Population Health Resear ch Unit (PHRU), which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford. The Oxford team was supported by an academic collaboration spanning eight countries, including the United States, Canada, Germany, China, Japan, Malaysia, Italy and the United Kingdom. EMPA-KIDNEY recruited over 6000 volunteers with chronic kidney disease to participate in the trial, as well as many kidney, diabetes and other medical speciality healthcare teams around the world who helped make the study possible... EMPA-KIDNEY was designed to test a medication called empagliflozin which was originally developed to treat high blood sugar in people with diabetes. Empagliflozin causes blood sugar (equivalent to 10 teaspoons a day) to pass into the urine. It likely also increases the amount of salt (sodium) passing into the urine. This..

Primary location: Oxford United Kingdom